Medtronic gains upper hand in AGA patent action
This article was originally published in Clinica
Medtronic has gained the advantage in its patent dispute with AGA Medical after a US district jury court in San Francisco ruled in the former’s favour during the first phase of the trial. The jury found that AGA’s Amplatzer occluder and vascular plug product lines infringed two Medtronic patents and ordered AGA to make a $57m payment to Medtronic, a fee which AGA claims is only “about half of what Medtronic had originally sought”. AGA will also make royalty payments of 11% on future US sales of the infringing devices through 2018. The second, non-jury phase is scheduled for later this year. Medtronic is also currently asserting these patents in a separate case against WL Gore due to begin in the same court on August 31.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals